Publications and communications of Céline Fombellida-Lopez

Buanec, H. L., Schiavon, V., Merandet, M., How-Kit, A., Bergerat, D., Fombellida-Lopez, C., Bensussan, A., Bouaziz, J.-D., Burny, A., Darcis, G., Song, H., Sajadi, M. M., Kottilil, S., Gallo, R. C., & Zagury, D. (19 March 2024). Early elevated IFNα is a key mediator of HIV pathogenesis. Communications Medicine, 4 (1), 53. doi:10.1038/s43856-024-00454-6

Le Buanec, H., Schiavon, V., Merandet, M., How-Kit, A., Song, H., Bergerat, D., Fombellida-Lopez, C., Bensussan, A., Bouaziz, J.-D., Burny, A., Darcis, G., Sajadi, M. M., Kottilil, S., Zagury, D., & Gallo, R. C. (19 March 2024). IFNα induces CCR5 in CD4+ T cells of HIV patients causing pathogenic elevation. Communications Medicine, 4 (1), 52. doi:10.1038/s43856-024-00453-7

Fombellida-Lopez, C., Berkhout, B., Darcis, G., & Pasternak, A. O. (2024). Persistent HIV-1 transcription during ART: time to reassess its significance? Current Opinion in HIV and AIDS. doi:10.1097/COH.0000000000000849

Fombellida-Lopez, C. (15 November 2023). 26-color panel for deep immunophenotyping of HIV-1 infected individuals [Paper presentation]. 26ème congrès annuel de l'Association Française de Cytométrie (AFC 2023), Toulouse, France.

Fombellida-Lopez, C. (05 October 2023). Deep Immunophenotyping of HIV-1 Infected Individuals [Paper presentation]. SONY ID7000 Spectral User's meeting, Paris, France.

Fombellida-Lopez, C., Pasternak, A. O., Cicilionyté, A., Maes, N., Vanwinge, C., Ormenese, S., Ladang, A., Cavalier, E., Winchester, L., Fletcher, C., SUSIN, F., VAIRA, D., Hayette, M.-P., Reenaers, C., Moutschen, M., & Darcis, G. (11 September 2023). Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults [Poster presentation]. HIV Cure Symposium 2023, Gand, Belgium.

Le Buanec, H., Schiavon, V., Merandet, M., How-Kit, A., Bergerat, D., Fombellida-Lopez, C., Bensussan, A., Bouaziz, J.-D., Burny, A., Darcis, G., Song, H., Sajadi, M. M., Kottilil, S., Gallo, R. C., & Zagury, D. (2023). Early Elevated IFNα Identified as the Key Mediator of HIV Pathogenesis and its low level a Hallmark of Elite Controllers. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/308341. doi:10.21203/rs.3.rs-2813601/v1

Le Buanec, H., Schiavon, V., Merandet, M., How-Kit, A., Song, H., Bergerat, D., Fombellida-Lopez, C., Bensussan, A., Bouaziz, J.-D., Burny, A., Darcis, G., Sajadi, M. M., Kottilil, S., Zagury, D., & Gallo, R. C. (2023). IFNα induces CCR5 in CD4+ T-cells, causing its anti- HIV inefficiency and its subsequent pathogenic elevation, partially controlled by anti-HIV therapy. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/308342. doi:10.21203/rs.3.rs-2813616/v1

Fombellida-Lopez, C. (18 March 2023). Impact of treatment simplification and intensification on HIV reservoirs [Paper presentation]. Expert to expert forum (ViiV), Anvers, Belgium.

Fombellida-Lopez, C., Pasternak, A. O., Cicilionyté, A., Maes, N., Vanwinge, C., Ormenese, S., Ladang, A., Cavalier, E., Winchester, L., Fletcher, C., SUSIN, F., VAIRA, D., Hayette, M.-P., Reenaers, C., Moutschen, M., & Darcis, G. (21 February 2023). Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults [Poster presentation]. Conference on Retroviruses and Opportunistic Infection (CROI 2023), Seattle, United States.

Fombellida-Lopez, C., Pasternak, A. O., Cicilionyté, A., Maes, N., Vanwinge, C., Ormenese, S., Ladang, A., Cavalier, E., Winchester, L., Fletcher, C., SUSIN, F., VAIRA, D., Hayette, M.-P., Reenaers, C., Moutschen, M., & Darcis, G. (23 November 2022). Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults [Poster presentation]. Belgium Research on AIDS and HIV Consortium (BREACH 2022), Bruxelles, Belgium.

Desmecht, S.* , Tashkeev, A.* , El Moussaoui, M., MARECHAL, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., Mni, M., Fouillien, N., TOUSSAINT, F., Gillet, L., Bureau, F., LUTTERI, L., HAYETTE, M.-P., MOUTSCHEN, M., MEURIS, C., ... DARCIS, G.*. (2022). Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -experienced subjects: impact of booster dose and breakthrough infections. Frontiers in Immunology, 13, 863554. doi:10.3389/fimmu.2022.863554
* These authors have contributed equally to this work.

Chaslain, A., Fombellida-Lopez, C., SUSIN, F., VAIRA, D., Moutschen, M., & Darcis, G. (September 2020). Obstacles à la guérison de l'infection par le VIH. Partie 2 : la réplication continue malgré le traitement. Revue Médicale de Liège, 75 (9), 582-587.

Fombellida-Lopez, C. (2020). Impact of treatments on HIV-1 latent reservoirs and ongoing viral replication [Master’s dissertation, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/260217

Fombellida-Lopez, C., Chaslain, A., SUSIN, F., VAIRA, D., Moutschen, M., & DARCIS, G. (September 2020). Obstacles à la guérison de l'infection par le VIH. Partie 1 : les réservoirs latents. Revue Médicale de Liège, 75 (9), 573-577.